FrancophonIA/ELRC3.0 huggingface dataset:
English: Very common symptoms in overdose (> 10 % incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Maltese: Sintomi komuni ħafna meta ittieħdet doża eċċessiva (>10% inċidenza) jinkludu takikardija, aġitazzjoni/aggressività, diżartrija, sintomi ekstrapiramidali varji, u telfien tas-sensi li tvarja minn sedazzjoni sa koma.
English: The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients.
Maltese: It-tabella li ġejja tiġbor fil-qosor ir-reazzjonijiet avversi rrapportati bi frekwenza akbar f'pazjenti adolexxenti (minn 13 sa 17-il sena) milli f'pazjenti adulti jew reazzjonijiet avversi li ġew identifikati biss waqt studji kliniċi ta' terminu qasir f'pazjenti adolexxenti.
English: Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Maltese: Epatite (inkluż mard tal-fwied tat-tip epatoċellulari, kolestatiku jew tattnejn flimkien)11
English: 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
Maltese: 15 Tibdil fil-livelli tal-kolesterol totali waqt is-sawm minn normali fil-linja bażi (< 4.39 mmol/l) għal għoljin (≥ 5.17 mmol/l) kien komuni.
English: 5 Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high (≥ 2.26
Maltese: Innotat għal livelli normali waqt is-sawm fil-linja bażi (< 1.69 mmol/l) li żdiedu għal għoljin (≥ 2.26
English: Very common: Weight gain 13, elevated triglyceride levels 14, increased appetite.
Maltese: Disturbi fil-metaboliżmu u n-nutrizzjoni Komuni ħafna: Żieda fil-piż 13, livelli elevati ta' trigliċeridi 14, żieda fl-aptit.
English: Absolute oral bioavailability relative to intravenous administration has not been determined.
Maltese: Il-biodisponibilità assoluta orali relattiva għal amministrazzjoni fil-vina ma kinitx determinata.
English: There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3 % versus 0.4 %, respectively).
Maltese: Kien hemm żieda ta' 3 darbiet akbar ta' CVAE f'pazjenti ttattati b'olanzapine, meta mqabblin ma' pazjenti ttrattati bil-plaċebo (1.3% kontra 0.4%, rispettivament).
English: • Increases in levels of uric acid and creatine phosphokinase in the blood
Maltese: • Żidiet fil-livelli tal-aċidu uriku u tal-creatine phosphokinase fid-demm
English: In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % versus 1.5 %, respectively).
Maltese: Fi studji kliniċi kkontrollati bil-plaċebo (li damu minn 6 sa 12-il ġimgħa ), fuq pazjenti anzjani (età medja 78 sena) li kellhom psikożi relatata mad-demenzja u/jew disturbi fil-komportament, kien hemm żieda ta' darbtejn akbar fl-inċidenza ta' mwiet fil-pazjenti ttrattati b'olanzapine, mqabbla ma' pazjenti ttrattati bil-plaċebo (3.5% kontra 1.5%, rispettivament).
English: 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
Maltese: 13 Wara kura għal żmien qasir (medjan ta' tul ta' żmien ta' 22 ġurnata), żieda fil-piż ta' > 7% mil-linja bażi tal-piż tal-ġisem (kg) kienet komuni ħafna (40.6 %), ≥ 15% mil-linja bażi tal-piż tal-ġisem kienet komuni (7.1 %) u ≥ 25 % kienet komuni (2.5 %).
English: In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
Maltese: Fl-istess studji kliniċi, kienu rrapportati avvenimenti avversi ċerebro-vaskulari (CVAE eż. puplesija, attakki iskemiċi momentanji) inklużi l-imwiet.
English: Following short term treatment (median duration 47 days), weight gain ≥ 7 % of baseline body weight was very common (22.2%), ≥ 15% was common (4.2%) and ≥25% was uncommon (0.8%).
Maltese: Wara kura għal żmien qasir (medjan ta' tul ta' żmien ta' 47 ġurnata), żieda fil-piż ta' ≥ 7% mil-linja bażi tal-piż tal-ġisem kienet komuni ħafna (22 %), ≥ 15% kienet komuni (4.2 %) u ≥ 25 % ma kinitx komuni (0.8 %).
English: Oedema
Maltese: Gamma
English: High Gamma Glutamyltransferase
Maltese: Glutamyltrans ferase għoli10
English: - High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Glenmark Europe.
Maltese: - Livell għoli ta' zokkor fid-demm u livelli għolja ta' xaħmijiet (trigliċeridi u kolesterol) instabu f'pazjenti li qed jieħdu Olanzapine Glenmark Europe.
English: Marketing Authorisation Holder Glenmark Arzneimittel GmbH Industriestr.
Maltese: Id-Detentur ta' l-Awtorizzazzjoni għat-tqegħid fis-Suq Glenmark Arzneimittel GmbH Industriestr.
English: Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l - < 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Maltese: Tibdil fit-trigliċeridi waqt is-sawm mil-limitu tan-normal fil-linja bażi (≥ 1.69 mmol/l- <2.26 mmol/l) għal għoljin (≥ 2.26 mmol/l) kienu komuni ħafna.
English: Olanzapine Glenmark Europe contains aspartame Olanzapine Glenmark Europe contains a source of phenylalanine.
Maltese: Olanzapine Glenmark Europe pillola li tinħall fil-ħalq fiha aspartame, li huwa sors ta' phenylalanine.
English: Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
Maltese: Il-pulmonite, iż-żieda fit-temperatura tal-ġisem, illetarġija, l-eritema, l-alluċinazzjonijiet viżivi u l-inkontinenza ta' l-awrina kienu komunement osservati.
English: • Restless legs syndrome
Maltese: • Sindromu ta' saqajn irrikwieti
English: EU/1/09/588/010 EU/1/09/588/011 EU/1/09/588/012
Maltese: EU/1/09/588/011 EU/1/09/588/012
English: Olanzapine demonstrated a greater in vitro affinity for serotonin 5 HT2 than dopamine D2 receptors and greater 5HT2 than D2 activity in vivo, models.
Maltese: Olanzapine wera affinità akbar in vitro għal serotonin 5HT2 milli għarriċetturi ta' dopamine D2 u attività in vivo akbar għal 5HT2 milli għal D2.
English: A mass balance study showed that approximately 57 % of radiolabelled olanzapine appeared in urine, principally as metabolites.
Maltese: Studju ta' tqabbil tal-piżijiet wera bejn wieħed u ieħor 57% ta' olanzapine radjuattiv fl-awrina, prinċipalment bħala prodotti metaboliċi.
English: How to store Olanzapine Glenmark Europe
Maltese: Tiħux Olanzapine Glenmark Europe:
English: Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
Maltese: Olanzapine ma ikkawżatx mutaġeniċità jew klastoġeniċità f'firxa sħiħa ta' testijiet standard, li nkludew testijiet ta' mutazzjoni tal-mikrobi kif ukoll testijiet fuq il-mammiferi kemm in vitro kif ukoll in vivo.
English: Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥ 7 % from baseline body weight in 39.9 % of patients.
Maltese: Trattament b'olanzapine għal żmien twil (sa 12-il xahar) bl-għan ta' prevenzjoni ta' episodju ieħor f'pazjenti b'mard bipolari kien assoċjat ma' żieda ta' ≥ 7% mil-linja bażi tal-piż tal-ġisem f'39.9% talpazjenti.
English: Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Maltese: Olanzapine wera wkoll riżultati effikaċji li jistgħu jiġu kkumparati ma' haloperidol fit-termini tal-proporzjon ta' pazjenti f'remissjoni sintomatika minn manija u depressjoni f'6 u 12-il ġimgħa.
English: • muscle stiffness or spasms (including eye movements)
Maltese: • Ebusija tal-muskoli jew spażmi (inklużi movimenti fl-għajnejn).
English: During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Maltese: Waqt trattament b'olanzapine flimkien ma' lithium jew divalproex, żieda ta' ≥ 7% mil-linja bażi tal-piż tal-ġisem seħħet f'17.4% tal-pazjenti waqt it-trattament akut (sa 6 ġimgħat).
English: EU/1/09/588/001 EU/1/09/588/002
Maltese: EU/1/09/588/001 EU/1/09/588/002 EU/1/09/588/003
English: Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Maltese: Newtropenja, tromboċitopenja jew l-anemija riversibbli żviluppaw fi ftit klieb ittrattati b'8 jew 10 mg/kg/ġurnata (espożizzjoni totali ta' olanzapine [erja taħt il-kurva] hija 12 sa 15-il darba aktar minn dik ta' raġel mogħti doża ta' 12 mg).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains 10 mg olanzapine Excipient with known effect: Each orodispersible tablet contains 0.46 mg of aspartame For the full list of excipients, see section 6.1
Maltese: Kull pillola li tinħall fil-ħalq fiha 0.46 mg ta' aspartame Għal-lista kompluta ta' eċċipjenti, ara sezzjoni 6.1.
English: Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - < 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Maltese: Tibdil fil-livelli tal-kolesterol totali waqt is-sawm mil-limitu tannormal fil-linja bażi (≥ 4.39 - < 5.17 mmol/l) għal għoljin (≥ 5.17 mmol/l) kien komuni ħafna.
English: Olanzapine was started at 2.5 mg/day and titrated to a maximum of 15 mg/day based on investigator judgement.
Maltese: Olanzapine inbeda b'2.5 mg/ġurnata u żdied bil-mod għall-massimu ta' 15 mg/ġurnata ibbażat fuq il-ġudizzju tar-riċerkatur.
English: Photosensitivity reaction
Maltese: Disturbi filqalb
English: In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4).
Maltese: Fi studji kliniċi f'pazjenti anzjani bid-demenzja, trattament b'olanzapine kien assoċjat ma' inċidenza ogħla ta' mwiet u reazzjonijiet avversi ċerebro-vaskulari meta mqabbla mal-plaċebo (ara wkoll sezzjoni 4.4).
English: • Sleepiness
Maltese: • Dijabete
English: 6 In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.
Maltese: Fi studji kliniċi, l-inċidenza tal-marda ta' Parkinson u distonja f'pazjenti kkurati b'olanzapine kienet numerikament ogħla, imma statistikament mhux differenti b'mod sinifikattiv mill-plaċebo.
English: Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Maltese: Elevazzjonijiet li ma jurux sintomi ta' l-enzimi aminotransferases tal-fwied, alanine transferase (ALT), aspartate transferase (AST) għal żmien qasir kienu komuni, speċjalment fil-bidu tat-trattament.
English: 28 orodispersible tablets
Maltese: 20mg pilloli
English: The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/LDL/HDL cholesterol or triglycerides increased over time.
Maltese: Il-proporzjon ta' pazjenti li kellhom tibdil avvers, klinikament sinifikanti fiż-żieda fil-piż, filglucose,10 fil-kolesterol totali/LDL/HDL jew trigliċeridi żdied maż-żmien.
English: In an 18-month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.
Maltese: Fi studju ta' 18-il xhar f'pazjenti b'manija jew b'episodji mħallta stabbilizzati fuq olanzapine flimkien ma' stabilizzatur tal-burdata (lithium jew valproate), l-użu fit-tul ta' olanzapine flimkien ma' lithium jew il-valproate ma kienx statistikament sinifikanti superjuri għal-lithium jew għall-valproate waħdu biex jittardja r-rikorrenza bipolari, kif definit skond il-kriterji (dijanjostiċi) tas-sindromu.
English: Excipient with known effect: Each orodispersible tablet contains 0.23 mg of aspartame For the full list of excipients, see section 6.1
Maltese: Kull pillola li tinħall fil-ħalq fiha 0.23 mg ta' aspartame Għal-lista kompluta ta' eċċipjenti, ara sezzjoni 6.1.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 20 mg olanzapine
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola li tinħall fil-ħalq fiha 20 mg olanzapine.
English: Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Maltese: Pazjenti kkurati b' mediċini antipsikotiċi, inkluż olanzapine, għandhom ikunu taħt osservazzjoni għal sinjali u sintomi ta' ipergliċemija (bħal polidipsja, polijurja, polifaġja u debbulizza) u pazjenti bid-dijabete mellitus jew li għandhom fatturi ta' riskju għad-dijabete mellitus għandhom jiġu segwiti b'mod regolari f'każ li l-kontroll tal-glukosju jmur għall-agħar.
English: Animal behavioural studies with olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile.
Maltese: Studji fuq l-imġiba ta' l-annimali li ingħataw olanzapine indikaw antagoniżmu għal 5HT, għal dopamine, u għal dak kolinerġiku, konsistenti mal-profil tarriċettur li jorbot.
English: There is a risk of feeling drowsy when you are given Olanzapine Glenmark Europe.
Maltese: Effetti sekondarji possibbli Kif taħżen Olanzapine Glenmark Europe.
English: 4 Observed for fasting normal levels at baseline (< 5.56 mmol/l) which increased to high (≥ 7 mmol/l).
Maltese: Innotat għal livelli normali waqt is-sawm fil-linja bażi (< 5.56 mmol/l) li żdiedu għal għoljin
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 15 mg olanzapine.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola li tinħall fil-ħalq fiha 15 mg olanzapine.
English: Clinical signs included sedation, ataxia, tremors, increased heart rate, labored respiration, miosis, and anorexia.
Maltese: Sinjali kliniċi inkludew sedazzjoni, atassja, rogħda, żjieda fir-rata tal-qalb, diffikultà fir-respirazzjoni, tidjiq tal-pupilla ta' lgħajn, u l-anoreksja.
English: Children and adolescents Olanzapine Glenmark Europe is not for patients who are under 18 years.
Maltese: Tfal u adolexxenti Olanzapine Glenmark Europe mhux għal pazjenti li għandhom anqas minn 18-il sena.
English: There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.
Maltese: Kien hemm rapporti ta' aġitazzjoni, ipertonja, ipotonja, rogħda,ħedla, skumdità respiratorja, jew disturb fit-tmigħ.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains 15 mg Olanzapine Excipient with known effect: Each orodispersible tablet contains 0.69 mg of aspartame For the full list of excipients, see section 6.1
Maltese: Kull pillola li tinħall fil-ħalq fiha 0.69 mg ta' aspartame Għal-lista kompleta ta' eċċipjenti, ara sezzjoni 6.1.
English: Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of approximately 2 g of oral olanzapine.
Maltese: Ġew rappurtati każijiet fatali b'dożi akuti u eċċessivi baxxi daqs 450 mg iżda kien hemm ukoll każ fejn pazjent baqa' ħaj wara doża eċċessiva akuta ta' madwar 2 g ta' olanzapine meħud b'mod orali.
English: 14 Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high
Maltese: Innotat għal livelli normali waqt is-sawm fil-linja bażi (< 1.016 mmol/l) li żdiedu għal għoljin (≥
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 5 mg olanzapine.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola li tinħall fil-ħalq fiha 5 mg olanzapine.
English: If you take more Olanzapine Glenmark Europe than you should Patients who have taken more Olanzapine Glenmark Europe than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Maltese: Jekk tieħu Olanzapine Glenmark Europe aktar milli suppost Pazjenti li ħadu iżjed Olanzapine Glenmark Europe milli suppost kellhom dawn is-sintomi li ġejjin: tħabbit mgħaġġel tal-qalb, aġitazzjoni/aggressività, problemi biex jitkellmu, movimenti mhux tas-soltu (speċjalment tal-ħalq u ta' l-ilsien) u tnaqqis fil-livell ta' koxjenza.
English: Olanzapine Glenmark Europe 20 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL' debossed on one side and ‘F' debossed on other side.
Maltese: Olanzapine Glenmark Europe 20 mg: pilloli li jinħallu fil-ħalq, tondi, ċatti, kulur isfar bil-ġnub imċanfrin b'‘OL' imnaqqxa fuq naħa waħda u b'‘F' imnaqqax fuq in-naħa l-oħra.
English: Olanzapine Glenmark Europe 5 mg orodispersible tablets Olanzapine
Maltese: Olanzapine Glenmark Europe 5 mg pilloli li jinħallu fil-ħalq Olanzapine
English: Cytochromes P450-CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Maltese: Il-prodott metaboliku li l-aktar jiċċirkola huwa 10-N- glukoronide, li ma jaqsamx il-barriera bejn id-demm u l-moħħ. Lenzimi ċitokromju P450-CYP1A2 u P450-CYP2D6 jikkontrbwixxu għall-formazzjoni ta' prodotti metaboliċi tat-tip N-desmethyl u 2-hydroxymethyl.
English: • Extreme tiredness.
Maltese: • Stitikezza.
English: Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/l) to high (≥ 7 mmol/l) were very common.
Maltese: Tibdil fil-livelli taz-zokkor waqt is-sawm mil-limitu tan-normal fil-linja bażi (≥ 5.56< 7 mmol/l) għal għoljin (≥ 7m mol/l) kienu komuni ħafna.
English: In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.
Maltese: Fi studju ta' terapija ta' pazjenti trattati flimkien b'lithium jew b'valproate għal minimu ta' ġimagħtejn, iż-żjieda ta' olanzapine 10 mg (terapija flimkien ma' lithium jew valproate) wara 6 ġimgħat irriżultat fi tnaqqis akbar tas-sintomi tal-manija milli b'monoterapija b'lithium jew b'valproate.
English: Fatigue Oedema Pyrexia10
Maltese: FULJETT TA' TAGĦRIF
English: Age > 75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment.
Maltese: L-età ta' > 75 sena u ddemenzja tat-tip vaskulari jew imħallta kienu identifikati bħala fatturi ta' riskju għal CVAE f'assoċjazzjoni ma' trattament b'olanzapine.
English: Olanzapine Glenmark Europe 20 mg orodispersible tablets Olanzapine
Maltese: Olanzapine Glenmark Europe 20 mg pilloli li jinħallu fil-ħalq Olanzapine
English: Olanzapine also showed a statistically significant advantage over placebo in terms of preventing either recurrence into mania or recurrence into depression.
Maltese: Olanzapine uriet ukoll vantaġġ statistiku u sinifikanti fuq il-plaċebo fil-prevenzjoni, kemm f'attakki ġodda ta' manija kif ukoll f'attakki ġodda ta' depressjoni.
English: In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy.
Maltese: Fi studju b'doża waħda orali (10 mg) fejn intużat it-Tomografija bl-Emissjoni tal-Pozitroni (PET) f'voluntiera b'saħħithom, olanzapine ipproduċa okkupanza ta' 5HT2A ogħla mir-riċettur ta' dopamine D2. Ma' dan, studju ta' immaġni ta' Tomografija Kkomputerizzata bl-Emissjoni ta' Foton Wieħed SPECT f'pazjenti skiżofreniċi wera li l-pazjenti li jirreaġġixxu għal olanzapine kellhom okkupanza strijatali
English: Olanzapine Glenmark Europe 15 mg orodispersible tablets Olanzapine
Maltese: Olanzapine Glenmark Europe 15 mg pilloli li jinħallu fil-ħalq olanzapine
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 10 mg olanzapine.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola li tinħall fil-ħalq fiha 10 mg olanzapine.
English: Thrombocytopenia11
Maltese: Eosinofilja Lewkopenija10 Newtropenija10
English: Olanzapine Glenmark Europe 10 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL' debossed on one side and ‘D' debossed on other side.
Maltese: Olanzapine Glenmark Europe 10 mg: pilloli li jinħallu fil-ħalq, tondi, ċatti, kulur isfar bil-ġnub imċanfrin b'‘OL' imnaqqxa fuq naħa waħda u b'‘D' imnaqqax fuq in-naħa l-oħra.
English: Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.
Maltese: Għalkemm ma sarux studji kliniċi magħmulin biex iqabblu l-adolexxenti ma' l-adulti, informazzjoni millistudji ta' ladolexxenti ġiet imqabbla ma' dik ta' l-istudji ta' l-adulti.
English: Read the package leaflet before use.
Maltese: Jista' jkun li mhux il-pakketti tad-daqsijiet kollha jkunu għal skop kummerċjali.
English: Olanzapine Glenmark Europe 10 mg orodispersible tablets Olanzapine
Maltese: Olanzapine Glenmark Europe 10 mg pilloli li jinħallu fil-ħalq Olanzapine
English: - Weight gain has been seen in patients taking Olanzapine Glenmark Europe.
Maltese: - Instab li kien hemm żieda fil-piż f'pazjenti li qed jieħdu Olanzapine Glenmark Europe.
English: Olanzapine Glenmark Europe 15 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL' debossed on one side and ‘E' debossed on other side.
Maltese: Olanzapine Glenmark Europe 15 mg: pilloli li jinħallu fil-ħalq, tondi, ċatti, kulur isfar bil-ġnub imċanfrin b'‘OL' imnaqqxa fuq naħa waħda u b'‘E' imnaqqax fuq in-naħa l-oħra.
English: Seizures where in most cases a history of seizures or risk factors for seizures were reported11
Maltese: Aċċessjonijiet li fil-maġġoranza tagħhom kien rrappurtat passat mediku ta' aċċessjonijiet jew fatturi tar-riskju għallaċċessjonijiet11
English: In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr).
Maltese: F'pazjenti b'mard tal-kliewi (tneħħija tal-krejatinina <10 ml/min) f'paragun ma' pazjenti b'saħħithom, ma kienx hemm differenza sinifikanti fil-medja tal-half life ta' l-eliminazzjoni (37.7 kontra
English: Amenorrhea Breast enlargement Galactorrhea in females Gynaecomastia/breast enlargement in males
Maltese: Ħruġ eċċessiv jew spontanju talħalib mis-sider Ginekomastija/tka bbir żejjed tassider fl-irġiel
English: Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day.
Maltese: Id-doża rakkomandata tal-bidu hija 10 mg/ġurnata.
English: Olanzapine Glenmark Europe has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
Maltese: Ġie muri li Olanzapine Glenmark Europe jippreveni li dawn is-sintomi jerġgħu jseħħu f'pazjenti bipolari, fejn l-episodju ta' manija rrisponda għall-kura b'olanzapine.